Salim Dhanji
Chief Executive Officer at ME THERAPEUTICS HOLDINGS INC.
Net worth: 20 M $ as of 2024-04-29
Profile
Salim Zulifkar Dhanji is currently the Chief Executive Officer & Executive Director at ME Therapeutics Holdings, Inc. since 2023 and the President at Perceptive Property Development since 2013.
He previously worked as the Director-Preclinical Research at Qu Biologics, Inc. from 2009 to 2014.
Dr. Dhanji received his undergraduate degree in 2001 and his doctorate in 2006 from the University of British Columbia.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-02-04 | 4,175,143 ( 17.72% ) | 20 M $ | 2024-04-29 |
Salim Dhanji active positions
| Companies | Position | Start |
|---|---|---|
| ME THERAPEUTICS HOLDINGS INC. | Chief Executive Officer | 2023-03-08 |
Former positions of Salim Dhanji
| Companies | Position | End |
|---|---|---|
Qu Biologics, Inc.
 Qu Biologics, Inc. BiotechnologyHealth Technology Qu Biologics, Inc. develops site specific immunomodulators that aim to restore the body's innate immune system to treat cancer. The firm specializes in ulcerative colitis, Crohn's disease, arthritis, cancer, autoimmune diseases, autoimmune disorders, inflammatory bowel disease, IBD, Site Specific Immunomodulators, immunotherapies, investigational drug, auto-immune, pharmaceuticals, research, inflammation, biotech and clinical trials. The company was founded by Harold David Gunn and Rob Freeman in 2007 and is headquartered in Burnaby, Canada. | Corporate Officer/Principal | 2013-12-31 |
Training of Salim Dhanji
| University of British Columbia | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ME THERAPEUTICS HOLDINGS INC. | Health Technology |
| Private companies | 1 |
|---|---|
Qu Biologics, Inc.
Qu Biologics, Inc. BiotechnologyHealth Technology Qu Biologics, Inc. develops site specific immunomodulators that aim to restore the body's innate immune system to treat cancer. The firm specializes in ulcerative colitis, Crohn's disease, arthritis, cancer, autoimmune diseases, autoimmune disorders, inflammatory bowel disease, IBD, Site Specific Immunomodulators, immunotherapies, investigational drug, auto-immune, pharmaceuticals, research, inflammation, biotech and clinical trials. The company was founded by Harold David Gunn and Rob Freeman in 2007 and is headquartered in Burnaby, Canada. | Health Technology |
- Stock Market
- Insiders
- Salim Dhanji
